Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

BerGenBio (Norway) a commercial-stage RNAi-based drug target validation clinical research organization, closed a $1.3M Series A financing. Participants include the Sarsia Seed and Development fund.

Dicerna Pharmaceuticals (Cambridge, MA) a development-stage biopharmaceutical company focused on the development RNAi-based therapeutics, closed a $4M Series B financing, bringing the total round to $29M. Participants include SR One, Domain Associates, Oxford Bioscience Partners, Abingworth Management and Skyline Ventures.

Dicerna Pharmaceuticals (Cambridge, MA) a development-stage biopharmaceutical company focused on the development RNAi-based therapeutics, closed a $25M Series B financing. Participants include Domain Associates, Oxford Bioscience Partners, Abingworth Management and Skyline Ventures.

Mirina (Seattle, WA) a development-stage biotechnology company focused on miRNA therapeutics for oncology and metabolic disorders, closed a $3.9M Series A financing, bringing the total round to $7.5M. Participants include Versant Ventures, Alexandria Real Estate Equities, ARCH Venture Partners, OVP Venture Partners and WRF Capital.

3-V Biosciences (Palo Alto, CA) a preclinical-stage biopharma company focused on broad-spectrum antivirals for respiratory viral infections, closed a $30M Series B financing. Participants include New Enterprise Associates, The Column Group and Kleiner Perkins Caulfield & Byers.

Traversa Therapeutics (La Jolla, CA) a preclinical-stage biopharmaceutical company developing RNAi delivery technologies, closed a $5M Series B financing. Participants include Morningside, Mesa Verde Venture Partners and Tech Coast Angels.

Intradigm (Palo Alto, CA) an early-stage developer of RNAi therapeutics with an initial focus on oncology, closed a $2.9M Series, bringing the round total to $21.4M. Participants include Astellas Venture Management, Lilly Ventures, Roche Venture Fund, MP Healthcare Venture Management, Frazier Healthcare Ventures, Alta Partners, MediBic Alliance Technology Fund and Novartis Venture Funds.

Prosena (The Netherlands) developer of RNA-based splice modulating therapeutics closed a $25M Series B financing. Participants include GIMV, AGF Management, Abingworth Management, Life Sciences Partnersand MedSciences Capital.

Intradigm (Palo Alto, CA) early-stage developer of RNAi-based oncology therapeutics, closed a $18.5M Series B financing. Participants include Lilly Ventures, Roche Venture Fund, MP Healthcare Venture Management, Frazier Healthcare Ventures, Alta Partners, MediBic Alliance Technology Fund and Novartis Venture Fund.

Biomics Biotechnologies (China) development-stage company focused on target identification and RNAi therapeutics, closed a $5M Series B financing. Participants include Jiangsu Dinghong Venture Capital and Jiangsu Benefit Rise Group.

Expression Genetics (Huntsville, AL) development-stage specialty biopharmaceutical company specializing in cancer immunotherapies for ovarian and cardiovascular disease, closed a $12M Series B financing. Participants include ?

Dicerna Pharmaceuticals (Watertown, MA) clinical-stage biopharmaceutical company developing RNAi therapeutics for multiple clinical applications, closed a $8.4M Series A. Participants include Abingworth, Oxford Bioscience Partners and Skyline Ventures.

Miragen (Boulder, CO) development-stage company focused on the treatment of cardiovascular and muscle disease based on microRNA biology, closed a $8M Series A financing. Participants include Atlas Venture and Boulder Ventures.

« Previous Entries  Next Page »

to top of page...